Newsletter · 2026-08-14 · Ashutosh Agarwal

Eli Lilly Runs Away With the Obesity Market as Payers Balk - The Healthcare Pulse - Week of August 14, 2026

How the sharpest healthcare and investing podcasts covered Eli Lilly's blockbuster quarter, the GLP-1 payer fight, and a dense FDA calendar, for the week of August 7 to 14, 2026.

The Healthcare Pulse

Week of August 7–14, 2026: Eli Lilly Runs Away With the Obesity Market as Payers Balk

What the sharpest healthcare podcasts, executives, and investors were actually saying this week, in plain English, with the numbers, names, and quotes that matter.

1. This Week at a Glance

If you listened to healthcare podcasts this week, one company was impossible to escape: Eli Lilly. Its blockbuster second-quarter results, nearly $15 billion of weight-loss and diabetes drug sales in a single quarter, set the tone for almost every conversation, from daily market shows to niche obesity-medicine podcasts. The running theme was that Lilly is "running away" with the obesity market while its Danish rival Novo Nordisk struggles to keep pace, though a few contrarians made the case that Novo is being unfairly written off.

The other big storylines:

• The obesity drug war went to court and to your pharmacy. Novo sued Lilly over its advertising, Lilly filed a fresh wave of lawsuits against sellers of black-market copycat drugs, and CVS very publicly patched up its relationship with Lilly, now selling these drugs for as little as $29 through its app.
• Who actually pays for these drugs became the real fight. Bank of America revealed a jaw-dropping $250 million annual bill for employee weight-loss drugs, even as many other big employers quietly dropped coverage. Several podcasts dug into why the math is so hard for employers and insurers.
• Washington rattled the sector. A surprise executive order to break up the standard childhood measles vaccine hit vaccine makers, and Affordable Care Act (ACA) insurance premiums are set to jump again, a median 15% for 2027.
• The year's biggest deal that wasn't. Reports emerged that AstraZeneca and Bristol Myers Squibb explored a roughly $400 billion merger, before the talks fell apart.
• Biotech's engine kept humming. A string of FDA decisions (some wins, some rejections), fresh cancer-drug data, and a Bristol Myers approval that landed early kept drug-development podcasts busy.

2. The People Driving the Conversation

Zaid Admani (The Rundown, Aug 6) delivered the cleanest summary of Lilly's quarter and why it stunned people:

"Eli Lilly is growing revenues by 48%, while Novo's revenues are down. So Eli Lilly continues to be the weight loss juggernaut. They now control roughly 61% of the U.S. obesity and diabetes drug market, compared to just 39% for Novo... So this might be a generational fumble by Novo Nordisk, because remember, they're the ones who launched this entire space with Ozempic a few years ago."

He also flagged the one blemish: Lilly's new weight-loss pill, orforglipron (sold as Foundayo), did about $98 million in sales, "just below the $103 million that Wall Street was expecting," and is "lagging behind Novo Nordisk's weight loss pill."

John Flavin (founder & CEO of Portal Innovations, on CNBC's Fast Money, Aug 4) was the week's most articulate Novo defender, a genuinely contrarian voice:

"I continue to feel that Novo is undervalued... anecdotally hearing from physicians a preference for the pill. It's cheaper than a shot... they're winning a race at two to one at this stage."

His nuance: Novo's oral Wegovy is the same molecule as its injection, while Lilly's pill uses a different molecule than its Zepbound shot, a subtle point he thinks doctors care about. On Novo's recent late-stage heart-outcomes trial failure, he called it "more of an optical disappointment... not really a major piece of analyst models going forward." Panelist Karen Finerman captured the pain of being on the other side, calling herself "a sad Novo holder for a long time."

Phil Rosen (Chief Market Strategist, ProCap Financial, on Schwab Network, Aug 6) gave the unabashed Lilly bull case, and cited the price targets flying around:

"This stock is best in class in biotech and GLP-1s. And I think GLP-1s are going to be the defining technology of the next decade right there with AI... they're probably going to be the first $2 trillion, $3 trillion pharma company in the world."

He noted Jefferies at a $1,440 target, Cantor at $1,410, and BMO at $1,400, and argued Lilly can "continue to grow earnings at over 20%," helped by aggressive acquisitions, AI-driven drug discovery, and even its own data-center investments.

Brian Moynihan (CEO, Bank of America, quoted on Morning Brew Daily, Aug 7) put a startling number on the employer side of the story:

"We spent about $250 million or more on GLPs... and that's up from zero four or five years ago."

That is about 13% of BofA's entire $2 billion health-care budget. Hosts Neil Freiman and Toby Howell used it to frame the central tension: employees love the benefit (one survey found 29% would switch jobs to get it), but most employers can't make the math work, only about a third of global employers cover the drugs, and 6% of large employers dropped weight-loss coverage in 2026.

Laura Dyrda (Becker's Healthcare, Aug 5) laid out the squeeze coming for anyone who buys insurance on their own:

"Those insurers are proposing a median rate increase of 15% for 2027. And that's the second straight year of double-digit hikes... insurers point to about a 10% median medical trend increase... thinking about GLP-1 drugs and demand usage there, provider consolidation."

She added that the expiration of enhanced government subsidies is "shrinking the risk pool" as healthier people drop coverage, leaving insurers with "a sicker and costlier pool of patients," and warned hospitals are bracing for more uninsured patients and unpaid bills.

Dr. Ken Cohen (Chief Medical Officer, Optum Health, on Managed Care Cast, Aug 11) presented research defending the much-criticized Medicare Advantage model (private insurers running Medicare benefits). His study of over 5 million patient-years found that when doctors take on "full risk" for a patient's total cost of care, the most socially vulnerable patients did meaningfully better, "23.4% to 30% fewer instances of high-risk medication uses," plus fewer hospital and ER visits. His key rebuttal to skeptics who claim these plans just cherry-pick healthy people: nearly 68% of full-risk Medicare Advantage members lived in high-vulnerability areas versus about 50% of traditional Medicare patients, evidence, he argued, that the population is sicker, not healthier.

3. The Key Debates

Debate 1: Is Novo Nordisk a value trap or a bargain?

• Bear (the consensus): On The Rundown, Zaid Admani framed Novo's decline as a possible "generational fumble." An anonymous biotech analyst on Full Signal (Aug 4) was blunter still, calling Novo "a value trap" while predicting Lilly becomes the first $2 trillion pharma company.
• Bull (the contrarian): John Flavin (Fast Money) argued the market gives Novo "not enough respect" for executing on its pill and that its core diabetes business is "spectacular." Fast Money's Karen Finerman held on purely "on valuation," while conceding the sentiment and management-turnover problems are real: "there's been very poor communication from management."
• The swing factor both sides agree on: the next-generation pipeline, Lilly's triple-hormone drug retatrutide versus Novo's CagriSema. On Diabetes Dialogue (Aug 4), doctors walked through Lilly's retatrutide Phase 3 data: about 21% weight loss (roughly 23 kg) in one diabetes trial and 23% (about 56 pounds) in another, alongside large drops in triglycerides and inflammation markers. That is the data the bulls are pointing to.

Debate 2: Should employers and insurers pay for GLP-1 weight-loss drugs at all?

• Yes, it's worth it: BofA's Moynihan said flatly "it's still the right thing to do," citing long-term health benefits and lower cardiovascular risk. Morning Brew cited an Aon study showing people on the drugs for 18 months had slower medical-cost growth and fewer hospitalizations.
• No, the math doesn't work: The counter, also on Morning Brew, is that the payoff is long-term while the cost is immediate, so employers like PwC have stopped covering the drugs for weight loss, and more plan to follow. On GLP-1 Hub (Aug 13), Andel CEO Jay Bregman argued insurers are "dropping GLP-1 coverage as costs rise" and that employers think in "short-term actuarial" windows that ignore benefits that accrue years later, often to a different insurer.
• A third view, cut out the middleman: Bregman, again on Off the Chart (Aug 13), claimed "less than 2% of people in any given plan actually access GLP-1s" because of prior authorizations and red tape, and pitched a direct-to-employer model with no prior authorization. Notably, he said Lilly and Novo have each opened their own direct-to-consumer channels, a structural shift that could squeeze the traditional pharmacy-benefit middlemen.

Debate 3: Is Medicare Advantage good for patients or just good for insurers?

• Defense: Optum's Dr. Ken Cohen (Managed Care Cast) marshaled five studies arguing full-risk models deliver better, more efficient care, especially for vulnerable patients.
• Criticism: On Becker's (Aug 5), Laura Dyrda described "a good number of denials coming through some of these plans," insurers exiting markets, and hospitals dropping their contracts. And on the Retire SMART Podcast (Aug 8), a host attacked the marketing side, alleging AARP promotes UnitedHealthcare plans as a "free premium" while the government pays UnitedHealthcare roughly $1,150 per month per senior, a conflict of interest, in his telling. It's a reminder that the political and public-relations backdrop for the big insurers remains hostile.

4. Hot Topics Under Debate

• CVS makes peace with Lilly. On The Morning Market Briefing (Aug 5), the hosts flagged a striking reversal: CVS, which "famously cut off Eli Lilly from its formulary this time last year," is now "best buds," offering GLP-1s for a one-time $29 through its app with transparent pricing and adding Zepbound to more plans from October 1. The reason, they argued, is self-interest: CVS's medical loss ratio (the share of premiums paid out in claims; lower is better for the insurer) improved to about 87% from nearly 90% a year earlier, as a healthier, GLP-1-using population files fewer claims.
• The copycat-drug crackdown. Lilly filed six new lawsuits on Aug 12 against U.S. sellers of black-market retatrutide and referred more than 200 entities to authorities. On Fat Science (Aug 10), Dr. Emily Cooper described a Yale "secret shopper" study (published in JAMA on July 6) finding that 45 of 49 websites selling GLP-1s online issued prescriptions, two-thirds with no clinician contact at all, often bundling in unapproved ingredients. The takeaway for investors: the branded makers are fighting a real gray market, and the outcome affects volumes.
• A Bristol Myers approval landed early. Bristol Myers won accelerated FDA approval on Aug 13 for Zenbexus (iberdomide) in multiple myeloma, the first approval in a new drug class, a few days ahead of its expected decision date. The data behind it: a 41% rate of the deepest treatment response versus 21% for the comparison regimen. It was a rare clean win in an otherwise noisy week for the company (more below).
• HIMS: love the business, distrust the boss. On Yet Another Value (Aug 7), investor Paul Cerro of Cedar Grove made one of the week's more colorful cases: he "wouldn't trust the CEO to walk his dog," yet stays long telehealth company Hims & Hers, arguing the market is fixated on its compounded-GLP-1 business while missing the real value in its data and customer-retention engine. It's a vivid example of the "great business, questionable management" debate running through the telehealth corner of healthcare.
• A cholesterol pill without the needle. On DoctorPodcasts | Cykiert Files (Aug 9), the host walked through Merck's newly FDA-approved oral cholesterol drug Lipfendra (an oral PCSK9 inhibitor), pitching it as "game-changing, without the injections," part of a broader theme of turning injectable blockbusters into pills.

5. Emerging Themes to Watch

• The "oral era" of obesity drugs. The whole competitive battle is shifting from weekly injections to daily pills, which are cheaper to make and easier to scale globally. Lilly's orforglipron pill got its first European green light this week: on Aug 10 the UK's medicines regulator became the first in Europe to authorize it (as Foundayo) for weight management and type 2 diabetes. On Decera Clinical Education (Aug 11), clinicians noted the pill's practical edge (it can be taken with food, unlike the older oral semaglutide) and that manufacturer direct-pay options keep improving affordability "monthly."
• AI moves from slideware to the pipeline. On Inside the ICE House (Aug 10), Takeda's science chief detailed AI's growing role in drug discovery. The Futurists (Aug 7) went bigger, pointing to tools like AlphaFold and AlphaGenome and the first FDA-cleared AI cancer-detection scan as signs AI will be embedded in everyday clinical practice "within two years." The flip side surfaced on NEXT with John Koetsier (Aug 13), which covered AI models now able to design DNA, and the biosecurity risk of AI-generated "deepfake viruses." Watch this as a dual-use story: enormous productivity upside, real regulatory and safety tail-risk.
• The pharmacy-benefit middleman is under siege from two directions. Manufacturers are opening direct-to-patient channels (per Jay Bregman above), and states are tightening the screws. On the Pharmacy Podcast Network (Aug 13), an Oklahoma pharmacist described independent pharmacies successfully forcing the big benefit managers, Caremark (CVS), Express Scripts, and Optum (UnitedHealth), to reimburse at invoice cost after "some fights," with Oklahoma's aggressive reform laws serving as a model for other states. Pressure on this profit pool is building.
• Health-system consolidation is accelerating. On Becker's (Aug 12), Alan Condon detailed a wave of hospital tie-ups, including an Intermountain Health–AdventHealth joint venture in Colorado combining eight hospitals and dozens of physician practices, expected to close in early 2027. Financial pressure on hospitals (recall Dyrda's point that 40% run in the red) is the driver.
• A quiet "healthcare bubble" question. The title of a Chip Stock Investor (Aug 12) episode, "The Healthcare Bubble No One's Talking About," captures a nascent worry about how much of the system's economics now rests on ever-rising drug spend and insurance premiums. It's early, but it's the kind of framing that can grow.

6. Stocks on the Radar

Direction reflects the tone of this week's podcast and news commentary, not a recommendation. "Mixed" means the discussion cut both ways.

7. Upcoming Catalysts (next ~2 weeks)

• ~Aug 15: Administrative cutoff in the second round of Medicare's drug-price negotiations (the "Maximum Fair Price" process), ahead of public disclosure. A slow-burn policy overhang for the biggest drugs.
• Aug 17: FDA decision on Merck/Pfizer/Astellas' Keytruda-plus-Padcev combination in bladder cancer; also a decision for Beren Therapeutics' rare-disease drug (Niemann-Pick type C).
• Aug 22: Two decisions: Capricor's Duchenne therapy (widely expected to be rejected or delayed after the negative advisory vote) and Savara's lung-disease drug molgramostim.
• Aug 23: Ultragenyx gene therapy (DTX401) for a rare metabolic disease.
• Aug 25: Jazz Pharmaceuticals/Zymeworks' Ziihera for stomach/esophageal cancer; Xspray's leukemia drug.
• Aug 27: Gilead's once-daily single-tablet HIV regimen (bictegravir/lenacapavir), a meaningful commercial catalyst.
• Aug 28: ITM/Lumara's radiopharmaceutical for neuroendocrine tumors.
• Aug 26 (earnings): Agilent (A) and Veeva Systems (VEEV) report; most big pharma has already reported this cycle.
• Sept 23 (looking ahead): The next major FDA advisory committee meeting: GRAIL's Galleri multi-cancer early-detection test.

8. The Bottom Line

This was a week that crystallized the single most important divide in healthcare investing right now: the enormous, still-accelerating value being created by obesity drugs versus the growing question of who is willing to pay for them. Eli Lilly's numbers were so dominant that even its skeptics mostly argued about degree, not direction, and the smart-money debate has shifted from "will these drugs sell" to "who captures the profits as the battle moves to cheaper pills, direct-to-patient sales, and squeezed middlemen."

Underneath that headline, the sector's other tensions all rhymed with the same theme of cost. ACA premiums are jumping again, employers are backing away from the very drugs their workers want most, insurers are fighting to keep their claims ratios down, and Washington is applying pressure from drug pricing to vaccine policy. Against that, the innovation engine keeps delivering: a Bristol Myers approval that beat its own deadline, promising cancer and heart data, and AI creeping from the pitch deck into the actual lab.

For investors, the practical read from the podcasts: the winners (Lilly, and increasingly the companies turning injections into pills or cutting out middlemen) are pulling away, while the payers and the political backdrop grow more contentious. The next two weeks bring a dense run of FDA decisions, several of them genuine coin-flips, that will test whether the biotech optimism is earned.